From one blockbuster class to a new peptide paradigm

GLP-1 receptor agonists have demonstrated that peptide medicines can achieve large-scale clinical use across major areas of metabolic disease. Researchers are now investigating increasingly sophisticated peptide therapeutics, including molecules that activate more than one receptor pathway, alongside approaches designed to produce more selective or tissue-specific effects.The significance is not simply that there may be a “next GLP-1”, it is that the success of GLP-1s could accelerate a broader shift towards designing peptide therapies around specific biological pathways and combinations of pathways.

Instead of asking whether one existing medicine can be repurposed for another disease, the industry can increasingly ask a different question: Can we design the next peptide specifically for the biology we want to change?

The brain is an especially interesting frontier The brain presents some of the hardest problems in drug development, with metabolism, inflammation, reward and cognition interconnected rather than isolated systems.That makes the emerging interest in GLP-1 biology particularly intriguing. GLP-1 signaling is involved in systems associated with appetite and reward, while researchers are investigating potential relationships with neurodegeneration and neuropsychiatric outcomes.

There are already signals worth investigating

A 2026 systematic review and meta-analysis of 82 studies identified potentially interesting signals across several neuropsychiatric outcomes, including Parkinson’s disease and binge-eating, but substantial heterogeneity and limitations across the evidence base mean that many of these findings remain hypothesis-generating. The brain story has already delivered an important reality check. In 2026, the phase 3 EVOKE and EVOKE+ trials found that oral semaglutide did not slow clinical progression in people with early Alzheimer’s disease. The result is a useful reminder that biological plausibility and encouraging observational signals do not necessarily translate into clinical benefit.

But a negative trial of one GLP-1 medicine in one neurological disease does not close the broader question of what peptide biology might achieve. It may instead sharpen it: which pathways, which Patients, which diseases and which peptide designs are most likely to matter? That distinction is important. The future of peptides should not be built on extrapolating beyond the evidence. It should be built on learning from the signals that justify better questions. The next generation of peptide therapies may prove even more interesting than the first, with the real opportunity potentially lying beyond today’s GLP-1 medicines as the field moves towards multi-pathway approaches and increasingly selective biological effects.That creates potentially important possibilities across metabolic, neurological and behavioral medicine.

For example, researchers are exploring questions around: appetite and satiety, reward and compulsive behavior, addiction, neuroinflammation, cognitive decline and neurodegeneration. But the evidence must move with the ambition. There is a temptation, whenever a blockbuster medicine reveals an unexpected biological possibility, to jump directly from mechanism to medical promise.We should resist that. Observational findings can generate important hypotheses, but they cannot establish clinical benefit. The future of peptide medicine will depend on whether promising biological signals survive increasingly rigorous clinical testing.

Not by the most exciting headline, but by evidence that translates into meaningful Patient outcomes.

From GLP-1s to a platform for discovery

Perhaps the most important legacy of GLP-1s will be conceptual. Their success has demonstrated the potential for peptide medicines to act across interconnected aspects of human physiology at a clinically relevant scale.

Rather than viewing peptides as a narrow drug class, the industry can increasingly think of them as a platform for exploring interconnected biological systems; particularly where metabolism, inflammation, appetite, reward and cognition intersect.

And this is where the patient voice becomes increasingly important Patients may care not only about whether a treatment changes a clinical measure, but whether it affects cognition, function, behavior, treatment burden or quality of life.

Clinical trials are essential for establishing efficacy and safety under defined conditions; real-world evidence can help us understand how it is experienced at scale, and patient-generated data can reveal something different again: what people actually notice, value, fear and struggle with in everyday life.

Patients may care not only about whether a treatment changes a clinical measure, but whether it affects cognition, function, behavior, treatment burden or quality of life.

The peptide era may be bigger than the GLP-1 era

It is too early to know whether GLP-1 medicines will genuinely produce an “Ozempic moment” in brain health. The clinical evidence does not yet justify that conclusion.

But perhaps that is not the most important question. The more interesting possibility is that GLP-1s could open the door to something much larger: a new generation of peptide medicines designed to explore increasingly complex relationships between metabolism, behavior, inflammation and the brain.

References 

• Beyond GLP-1: underexplored peptide–receptor systems as the next frontier in drug discovery
• Evaluating the clinical effects of glp-1 receptor agonists for Alzheimer’s and Parkinson’s diseases using minimal clinically important difference: systematic review and meta-analysis
• The evolving landscape of obesity pharmacotherapy
• The brain may be about to have itsOzempic moment